Anti-BCMA CAR-T cells is under clinical development by Eugia Pharma Specialties and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Anti-BCMA CAR-T cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Anti-BCMA CAR-T cells overview

Gene-modified cell therapy is under development for the treatment of relapsed and refractory multiple myeloma (RRMM). The therapeutic candidate comprises autologous T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing BCMA. It is administered through intravenous route.

Eugia Pharma Specialties overview

Eugia Pharma Specialties is a pharmaceutical company. It specialises in the development of sophisticated injectable hormonal and cancer drugs. The company is headquartered in India.

For a complete picture of Anti-BCMA CAR-T cells’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.